Exxel Pharma

Executive Summary

Exxel Pharma is a privately held, clinical-stage biopharmaceutical company developing novel small molecule therapeutics for neuronal hypersensitivity disorders. Its lead candidate, EX937, is a peripherally-acting FAAH inhibitor initially targeting refractory chronic cough, with potential expansion into migraine, neuropathic pain, and hyperactive bladder. Founded in 2016 and headquartered in Basking Ridge, New Jersey, the company leverages a differentiated mechanism to avoid central nervous system side effects. While still in early clinical development, EX937 has the potential to address significant unmet needs in chronic cough, a condition with limited treatment options. The company's focus on peripherally-restricted inhibition may offer a favorable safety profile, positioning it for partnerships or further investment as clinical data mature.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line results for EX937 in refractory chronic cough45% success
• TBDExpansion into additional indications (e.g., migraine or neuropathic pain) via IND filings30% success
• TBDPartnership or licensing agreement for EX937 or other assets35% success